Previous 10 | Next 10 |
EMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectiou...
2023-03-28 17:27:17 ET Gainers: Arcturus Therapeutics ( ARCT ) +15% . lululemon athletica ( LULU ) +11% . Fate Therapeutics ( FATE ) +5% . Kezar Life Sciences ( KZR ) +5% . Longboard Pharmaceuticals ( LBPH ) +4% . Losers: ...
2023-03-28 13:41:06 ET Vaccine-developer Gritstone bio ( NASDAQ: GRTS ) trended higher on Tuesday after B. Riley launched its coverage with a Buy rating and a 12-month target of $8 per share, noting its prospects in messenger RNA technology. The analyst Mayank Mamtani argues...
2023-03-21 00:06:20 ET Summary Today, we put our focus on a small developmental concern called Gritstone bio, Inc. Gritstone's most advanced program is in a registrational trial, and it also has a potentially significant collaboration deal with Gilead Sciences around a different p...
EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 2023 American Association for Cancer Research (AACR) Annual M...
2023-03-10 16:10:04 ET Gritstone bio ( NASDAQ: GRTS ) closed down ~8% after disclosing Friday afternoon it holds "less than $500K" in cash at FDIC-closed Silicon Valley Bank ( SIVB ) as well as a loan and security agreement with Hercules Capital and SVB. Under ...
2023-03-09 22:21:06 ET Gritstone bio Inc. (GRTS) Q4 2022 Earnings Conference Call March 09, 2023, 04:30 PM ET Company Participants George MacDougall - Director, Investor Relations and Corporate Communications Andrew Allen - Co-Founder, President, CEO and Director ...
2023-03-09 16:31:56 ET Gritstone Oncology press release ( NASDAQ: GRTS ): FY GAAP EPS of -$1.32 beats by $0.10 . Revenue of $19.95M (-58.6% Y/Y) beats by $1.36M . Cash, cash equivalents, marketable securities and restricted cash were $185.2 million as of Decemb...
-- Preliminary data from GRANITE Phase 2/3 study (individualized vaccine for first-line microsatellite-stable colorectal cancer [MSS-CRC]) remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals from “off-the-shelf” vaccine program (SLATE) consistent with those from GR...
2023-03-08 17:35:28 ET Major earnings expected after the bell on Thursday include: Oracle corporation ( ORCL ) DocuSign ( DOCU ) Wheaton Precious Metals Corp. ( WPM ) Bionano Genomics ( BNGO ) Ulta Beauty (ULTA0) For further details see: ...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024...